STOCK TITAN

PainReform to Present at the Microcap Conference in Atlantic City

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) announced its participation at The Microcap Conference on January 30 - February 1, 2024, where CEO Ilan Hadar will present on Track 2 and Track 5. The company will also hold one-on-one meetings with investors and provided contact information for meeting requests and conference registration.
Positive
  • None.
Negative
  • None.

TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

Ilan Hadar, CEO of the Company is scheduled to present on Wednesday, January 31st at 10:50 AM EST in Track 2 and Thursday, February 1st at 10:25 AM EST in Track 5. Management will also be participating in one-on-one meetings with qualified investors throughout the conference. To request a meeting, please contact prfx@crescendo-ir.com.

To register to attend The Microcap Conference, please follow this link.

About The Microcap Conference and DealFlow Events

Organized by DealFlow Events, this 3-day event at Caesars Atlantic City Hotel & Casino will feature company presentations from publicly traded microcap businesses and qualified private companies across healthcare, technology, financial services, energy, and other high-growth sectors. The conference facilitates extensive networking through 1-on-1 investor meetings and interactive activities and entertainment, including a poker tournament and exclusive concert with Soul Asylum.

In addition, keynote presentations and panel discussions led by industry experts will provide key insights into trading strategies, regulations, risk assessment and mitigation, tax issues, and other topics critical to the microcap community. Unlike many other microcap events, there’s no invitation required. For more information and to register for The Microcap Conference, please visit https://themicrocapconference.com/tickets/.

About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product is based on the local anesthetic ropivacaine, targeting the postoperative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended postoperative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com

Ilan Hadar
Chief Executive Officer
PainReform Ltd.
Tel: +972-54-5331725
Email: ihadar@painreform.com


The Microcap Conference is being held on January 30 - February 1, 2024.

The Microcap Conference is being held at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

CEO Ilan Hadar will be presenting on Wednesday, January 31st at 10:50 AM EST in Track 2 and Thursday, February 1st at 10:25 AM EST in Track 5.

Investors can request a meeting by contacting prfx@crescendo-ir.com.

To register to attend The Microcap Conference, one can follow this link.
PainReform Ltd

NASDAQ:PRFX

PRFX Rankings

PRFX Latest News

PRFX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing

About PRFX

painreform is a specialty pharmaceutical company that develops products for the treatment of pain. focused on reformulations of established pain drugs for the us fda 505(b)(2) regulatory pathway, painreform applies unique technologies to enhance efficacy, reduce adverse effects and increase convenience. our mission is to offer pain therapeutics with clinically meaningful benefits to both physicians and patients.